Their drug reduces lipids (fat) in the liver by inhibiting the HSD17B13 gene. Lipids will increase inflammation and fibrosis, CCR5 blockade has shown a reduction of lipids and will actively reduce inflammation and the fibrosis that follows.

It's possible that Arrowhead's drug could show positive results in NASH but I think leronlimab would be superior.